Literature DB >> 33613745

Clinicopathological and prognostic significance of Fusobacterium nucleatum infection in colorectal cancer: a meta-analysis.

Shu-Chen Huangfu1, Wen-Bin Zhang1, Hao-Ran Zhang1, Yang Li1, Yi-Ran Zhang1, Jin-Lin Nie1, Xiao-Dong Chu1, Chang-Shun Chen1, Hai-Ping Jiang1, Jing-Hua Pan1.   

Abstract

Background: This study aimed to clarify the relationship between F. nucleatum levels and the prognosis of CRC, which is still controversial.
Methods: Relevant articles were searched on PubMed, Web of Science, PMC and Embase up to April 7, 2020. Outcomes of interest included clinical characteristics, molecular characteristic and survival analysis. HR (OR), odds ratios (OR) and 95% confidence interval (CI) were calculated to explore the prognostic value and relationship of clinical characteristics of Fusobacterium nucleatum in CRC.
Results: A total of 3626 CRC patients from 13 eligible studies were included. High levels of F. nucleatum were associated with worse prognosis, as such parameters as overall survival (OS) (hazard ratio [HR] = 1.40, 95% confidence interval [CI]: 1.40 - 1.63, P < 0.0001), disease-free survival (DFS) (HR = 1.71, 95% CI: 1.29-2.26, P = 0.0002), and cancer-specific survival (OR= 1.93, 95% CI: 1.42-2.62, P <0.0001). F. nucleatum levels were related with T3-T4 stage (OR = 2.20, 95% CI: 1.66-2.91, P < 0.00001), M1 stage (OR = 2.11, 95% CI: 1.25-3.56, P = 0.005), poor tumor differentiation (OR = 1.83, 95% CI: 1.11-3.03, P =0.02), microsatellite instability-high (OR = 2.53, 95% CI: 1.53-4.20, P = 0.0003), and KRAS mutation (OR =1.27, 95% CI: 1.00-1.61, P=0.05) showed. Conclusions: High levels of F. nucleatum suggest a poor prognosis and are associated with tumor growth, distant metastasis, poor differentiation, MSI-high, and KRAS mutation in CRC patients. © The author(s).

Entities:  

Keywords:  Colorectal cancer; Fusobacterium nucleatum

Year:  2021        PMID: 33613745      PMCID: PMC7890333          DOI: 10.7150/jca.50111

Source DB:  PubMed          Journal:  J Cancer        ISSN: 1837-9664            Impact factor:   4.207


  5 in total

1.  Salivary Fusobacterium nucleatum serves as a potential biomarker for colorectal cancer.

Authors:  Xin Zhang; Yaping Zhang; Xinru Gui; Yanli Zhang; Zhenhong Zhang; Wendan Chen; Xiaowei Zhang; Yanxiang Wang; Mengjiao Zhang; Ziqi Shang; Yiwei Xin; Yi Zhang
Journal:  iScience       Date:  2022-04-04

Review 2.  A New Comorbidity in Periodontitis: Fusobacterium nucleatum and Colorectal Cancer.

Authors:  Francisco Mesa; Maria José Mesa-López; Juan Egea-Valenzuela; Cristina Benavides-Reyes; Luigi Nibali; Mark Ide; Giuseppe Mainas; Manfredi Rizzo; Antonio Magan-Fernandez
Journal:  Medicina (Kaunas)       Date:  2022-04-15       Impact factor: 2.948

3.  Prognostic and clinicopathological significance of Fusobacterium nucleatum in colorectal cancer: a systemic review and meta-analysis.

Authors:  Younghoon Kim; Nam Yun Cho; Gyeong Hoon Kang
Journal:  J Pathol Transl Med       Date:  2022-05-15

Review 4.  Prospects and Challenges of the Study of Anti-Glycan Antibodies and Microbiota for the Monitoring of Gastrointestinal Cancer.

Authors:  Eugeniy P Smorodin
Journal:  Int J Mol Sci       Date:  2021-10-27       Impact factor: 5.923

5.  Accuracy and Clinical Relevance of Intra-Tumoral Fusobacterium nucleatum Detection in Formalin-Fixed Paraffin-Embedded (FFPE) Tissue by Droplet Digital PCR (ddPCR) in Colorectal Cancer.

Authors:  José Guilherme Datorre; Ana Carolina de Carvalho; Mariana Bisarro Dos Reis; Monise Dos Reis; Marcus Matsushita; Florinda Santos; Denise Peixoto Guimarães; Rui Manuel Reis
Journal:  Diagnostics (Basel)       Date:  2022-01-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.